Biotech Collaboration Strategy With IGI's Cyril Konto, M.D.

On this week's episode, Cyril Konto, M.D., president, executive director, and CEO at Ichnos Glenmark Innovation (IGI) talks about the promise of multi-specific antibodies, funding the company during the 'biotech winter,' closing a $700 million upfront licensing deal with AbbVie, the impact of China's rising biotech sector, and the keys to successful collaboration. Cyril also discusses IGI's focus on developing innovative therapies for emerging markets, and the shift from animal models to in silico modeling in preclinical research.  

Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com.

Get in touch with guest and topic suggestions: ben.comer@lifescienceconnect.com

Find Ben Comer on LinkedIn https://www.linkedin.com/in/bencomer/

Find the Business of Biotech wherever you get your podcasts.